From the Filings: Biotech Edition

(Recent funding news based on Form D filings with the S.E.C.)

Heavily funded Intrexon Corp. has apparently added $17 million in new financing, according to a recent regulatory filing. The synthetic biology company previously raised more than $259 million from investors, including a $100 million round closed in May. Investors include Chief Executive Randal Kirk, NewVa Capital Partners and Third Security LLC. According to the filing, Blacksburg, Va.-based Intrexon plans to raise as much as $50 million in the round.

Pulse Therapeutics Inc. has raised $3 million in new financing, according to a regulatory filing. Pulse Therapeutics is based in St. Louis, Missouri, and is developing stroke treatment technology designed to destroy blood clots. Investors include St. Louis-based seed investor BioGenerator.

Heat Biologics, a Chapel Hill, N.C.-based biotech company, has raised $2.8 million in new funding. The company is aiming to raise as much as $4.1 million in the round, according to the filing. In May 2010, Heat Biologics announced an undisclosed amount of financing from Brightline Ventures.

ImmuneXcite Inc. has raised $2.4 million in equity financing, the company revealed in a recent federal filing. According to the ImmuneXcite website, the company’s technology platform is designed to increase the “efficacy of therapeutic monoclonal antibodies for oncological and infectious disease targets.” Investors in the company were not disclosed.

Koronis Pharma Inc., a Seattle-based developer of antiviral therapeutics, has raised $1 million of a planned $2 million round, according to a regulatory filing. The company is backed by investors including Helix Ventures. According to the company’s website, Helix General Partner Graham Crooke holds a board seat.